P.R. Herzig & Co’s Amicus Therapeutics FOLD Stock Holding History

P.R. Herzig & Co’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,000	Closed	-$156K	–	14
2018 Q2	$156K	Buy	+10,000	New	+$151K	0.34%	41
2015 Q2	–	Sell	-47,000	Closed	-$511K	–	48
2015 Q1	$511K	Sell	47,000 -6,000	-11%	-$52.9K	0.87%	37
2014 Q4	$441K	Hold	53,000	–	–	0.68%	44
2014 Q3	$315K	Hold	53,000	–	–	0.47%	47
2014 Q2	$177K	Hold	53,000	–	–	0.23%	53
2014 Q1	$110K	Hold	53,000	–	–	0.14%	62
2013 Q4	$125K	Hold	53,000	–	–	0.15%	60
2013 Q3	$123K	Hold	53,000	–	–	0.16%	61
2013 Q2	$123K	Buy	+53,000	New	+$163K	0.24%	41

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

P.R. Herzig & Co's FOLD Position: Q3 2018 in Review

P.R. Herzig & Co sold out of Amicus Therapeutics (FOLD) in Q3 2018, closing a stake of 10,000 shares — an estimated $156K sold.

P.R. Herzig & Co first reported a position in FOLD in Q2 2013 and held it in 9 quarters. The position peaked at $511K in Q1 2015. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2018.

P.R. Herzig & Co reported no remaining Amicus Therapeutics position as of Q3 2018 after selling out during the quarter.
P.R. Herzig & Co sold 10,000 Amicus Therapeutics shares in Q3 2018, an estimated $156K.
P.R. Herzig & Co first reported a position in Amicus Therapeutics in Q2 2013 and held it in 9 quarters.
P.R. Herzig & Co's Amicus Therapeutics position peaked at $511K in Q1 2015.
204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2018.

Based on P.R. Herzig & Co's 13F filing for Q3 2018.